Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 16:30 ET | Source: Rgenta Therapeutics

Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA...
April 21, 2026 16:10 ET | Source: CytoDyn Inc.

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc....
April 21, 2026 16:05 ET | Source: PharmAla Biotech

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla files Q2 quarterly financials with increased customer deposits.
April 21, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...
April 21, 2026 16:05 ET | Source: TELA Bio, Inc.

TELA Bio to Announce First Quarter 2026 Financial Results

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
April 21, 2026 16:01 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential...
April 21, 2026 16:00 ET | Source: Belite Bio, Inc

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE...
April 21, 2026 14:39 ET | Source: Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2025 was adopted. The Board of Directors’...
April 21, 2026 11:00 ET | Source: Remix Therapeutics

Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
April 21, 2026 10:42 ET | Source: Trethera Corporation

Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors

Drew Woodmansee Board Appointment strengthens Trethera with deep patent expertise and capital formation experience, supporting its next phase of growth.